StockTips Newsletter

Pick of The Week

BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Investment Considerations
  • BiondVax has an exclusive worldwide license to commercialize NanoAbs for the treatment of COVID-19.
  • The company plans to initiate a Phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023.
  • BiondVax has exclusive options for worldwide licenses for NanoAbs to treat other disorders with large, underserved needs.
  • The company has filed a Registration Statement with the SEC for an underwritten offering of shares.
Additional Resources
View Complete Profile


InvestorNewsBreaks - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q3 2022 Financial Results, Corporate Updates

November 30, 2022 9:45 AM

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company that focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting on its third quarter, the period ending Sept. 30, 2022; the report also included key company updates. Highlights of the report included the strategic research collaboration between BiondVax, the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen; the three companies are working to develop a pipeline of innovative nanosized antibody (“NanoAb”) therapies. The company is also working to regain compliance with NASDAQ listing rules regarding minimum shareholders’ equity and minimum share bid price; those efforts have included a ratio change between its ordinary shares and its American Depositary Shares (“ADSs”) traded on the Nasdaq exchange and submission of a plan to regain compliance with the minimum shareholders’ equity requirement. In addition, BiondVax reported net profit/loss numbers for Q3 2022 was a profit of NIS 3.7 million ($1.05 million) compared to a loss of NIS 9 million for Q3 2021. The report also showed R&D expenses for the quarter totaled NIS 3.9 million ($1.1 million) compared to NIS 2 million for Q3 2021; marketing, general and administrative expenses for the quarter reached NIS 3.3 million ($1 million) compared to NIS 6.0 million for the same quarter in 2021; and other income in the amount of NIS 11,201 ($3,161) as a result of the EIB loan revaluation. No additional other income was recorded in the first nine months of 2022. As of Sept. 30, 2022, BiondVax had cash and cash equivalents of NIS 29.4 million ($8.3 million) compared to NIS 54 million as of Dec. 31, 2021.
View Full Press Release

follow us on twitter    like us on facebook

Interact with other Small-Cap Enthusiuasts

Text STOCKTIPS to 844-397-5787

About StockTips

We focus on micro and small-cap companies in a variety of stages that demonstrate the products and/or services, management, business plan and drive needed to reach their valuation. The Small Cap market is teeming with opportunity - but where do you start, when and where do your research? StockTips is your guide to evaluate potential investments and market trends. We don't offer the golden (yet often lackluster) promise of the "hottest stocks" in today's market - we simply point you toward opportunities to get in on some of the market's ground-floor plays that are ready for you, hence we offer stock tips that may be ready right now.

Newsletter archives and disclaimers available at:

StockTips is part of the InvestorBrandNetwork.

Please read Disclaimers for Full Compensation Disclosures and other disclaimers.

Contact The Editor   |   Unsubscribe me from this mailing list

© 2019 StockTips (ST)